Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
2014 |
| gptkbp:ATCCode |
L04AC11
|
| gptkbp:brand |
Sylvant
|
| gptkbp:CASNumber |
541143-77-1
|
| gptkbp:contraindication |
severe infections
|
| gptkbp:developedBy |
gptkb:Janssen_Biotech
|
| https://www.w3.org/2000/01/rdf-schema#label |
siltuximab
|
| gptkbp:indication |
multicentric Castleman disease
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
chimeric monoclonal antibody
|
| gptkbp:mechanismOfAction |
binds to IL-6
|
| gptkbp:notRecommendedFor |
HHV-8-associated Castleman disease
HIV-positive Castleman disease |
| gptkbp:pregnancyCategory |
not assigned (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
pruritus
infections rash infusion reactions hyperuricemia |
| gptkbp:target |
gptkb:interleukin-6
|
| gptkbp:UNII |
3X2Q1FCQ6K
|
| gptkbp:usedFor |
gptkb:Castleman_disease
|
| gptkbp:bfsParent |
gptkb:interleukin-6
gptkb:human_interleukin-6 |
| gptkbp:bfsLayer |
6
|